BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15072597)

  • 1. Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer.
    Ikegami S; Tadakuma T; Ono T; Suzuki S; Yoshimura I; Asano T; Hayakawa M
    Cancer Sci; 2004 Apr; 95(4):367-70. PubMed ID: 15072597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.
    Ikegami S; Tadakuma T; Suzuki S; Yoshimura I; Asano T; Hayakawa M
    Jpn J Cancer Res; 2002 Oct; 93(10):1154-63. PubMed ID: 12417046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer.
    Hattori Y; Maitani Y
    Cancer Sci; 2006 Aug; 97(8):787-98. PubMed ID: 16800821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.
    Yoshimura I; Ikegami S; Suzuki S; Tadakuma T; Hayakawa M
    J Urol; 2002 Dec; 168(6):2659-64. PubMed ID: 12442005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated suicide gene therapy under the control of Cox-2 promoter for colorectal cancer.
    Wang ZX; Bian HB; Yang JS; De W; Ji XH
    Cancer Biol Ther; 2009 Aug; 8(15):1480-8. PubMed ID: 19571664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
    Uchida A; O'Keefe DS; Bacich DJ; Molloy PL; Heston WD
    Urology; 2001 Aug; 58(2 Suppl 1):132-9. PubMed ID: 11502468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
    Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
    Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Construction and expression of recombinant plasmid with prostate-specific membrane antigen promoter and enhancer regulating uracil phosphoribosyltransferase gene].
    Zhao FJ; Li H; Cheng HM; Zeng H; Wei Q; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):172-5. PubMed ID: 15807258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific targeting of prostate cancer cells in vitro by the suicide gene/prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer.
    Zhao FJ; Zhang S; Yu ZM; Xia SJ; Li H
    Prostate Cancer Prostatic Dis; 2009; 12(2):166-71. PubMed ID: 18626508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
    Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
    J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity.
    Cheon J; Kim HK; Moon DG; Yoon DK; Cho JH; Koh SK
    BJU Int; 2000 Apr; 85(6):759-66. PubMed ID: 10759680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth.
    Sung SY; Chang JL; Chen KC; Yeh SD; Liu YR; Su YH; Hsueh CY; Chung LW; Hsieh CL
    PLoS One; 2016; 11(4):e0153350. PubMed ID: 27054343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.
    Azatian A; Yu H; Dai W; Schneiders FI; Botelho NK; Lord RV
    J Gastrointest Surg; 2009 Jun; 13(6):1044-51. PubMed ID: 19277794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: growth inhibition of tumors and lack of localization in normal tissues.
    Takakuwa K; Fujita K; Kikuchi A; Sugaya S; Yahata T; Aida H; Kurabayashi T; Hasegawa I; Tanaka K
    Jpn J Cancer Res; 1997 Feb; 88(2):166-75. PubMed ID: 9119745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-step amplification of the human PPT sequence provides specific gene expression in an immunocompetent murine prostate cancer model.
    Dzojic H; Cheng WS; Essand M
    Cancer Gene Ther; 2007 Mar; 14(3):233-40. PubMed ID: 17053814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer.
    Chen Y; Wang G; Kong D; Zhang Z; Yang K; Liu R; Zhao W; Xu Y
    Mol Carcinog; 2013 Mar; 52(3):237-46. PubMed ID: 22161782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes.
    Yue QH; Hu XB; Yin Y; Su MQ; Cheng XD; Yang L; Zhou TC; Hao X
    Oncol Rep; 2009 Dec; 22(6):1341-7. PubMed ID: 19885585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer.
    Furuhata S; Ide H; Miura Y; Yoshida T; Aoki K
    Mol Ther; 2003 Mar; 7(3):366-74. PubMed ID: 12668132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
    Suzuki S; Tadakuma T; Asano T; Hayakawa M
    Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
    Liu R; Sun J; Zhang Z; Xu Y
    Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.